Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors
Lucía López(International Centre for Genetic Engineering and Biotechnology), Federica Benvenuti(International Centre for Genetic Engineering and Biotechnology), Nicoletta Caronni(The San Raffaele Telethon Institute for Gene Therapy), Federica La Terza(The San Raffaele Telethon Institute for Gene Therapy), Camilla Volponi(Humanitas University), Giovanni Germano(IFOM), Marc Dalod(Centre National de la Recherche Scientifique), Giuseppe Rospo(Boehringer Ingelheim (Austria)), Pierre Bourdely(Inserm), Simone Vodret(International Centre for Genetic Engineering and Biotechnology), Dejan Lazarević(Istituti di Ricovero e Cura a Carattere Scientifico), Pierre Guermonprez(Institut Pasteur), Francesca Giannese(Vita-Salute San Raffaele University), Luciano Gastón Morosi(International Centre for Genetic Engineering and Biotechnology), Alberto Bardelli(IFOM), Luigia Pace(Italian institute for Genomic Medicine), Patrizia Stoitzner(Universität Innsbruck), Valentina Russo(Italian institute for Genomic Medicine), Roberto M. Amadio(International Centre for Genetic Engineering and Biotechnology), Sonal Joshi(International Centre for Genetic Engineering and Biotechnology), Giulia Maria Piperno(International Centre for Genetic Engineering and Biotechnology)
Cited by 44
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Toward understanding and exploiting tumor heterogeneity
|Nature Medicine|2015|770